Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Rib Fracture | Research

Predictors and characteristics of Rib fracture following SBRT for lung tumors

Authors: Michael P. Carducci, Baskaran Sundaram, Benjamin A. Greenberger, Maria Werner-Wasik, Gregory C. Kane

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

The utilization of stereotactic body radiation therapy (SBRT) is increasing for primary and secondary lung neoplasms. Despite encouraging results, SBRT is associated with an increased risk of osteoradionecrosis-induced rib fracture. We aimed to (1) evaluate potential clinical, demographic, and procedure-related risk factors for rib fractures and (2) describe the radiographic features of post-SBRT rib fractures.

Methods

We retrospectively identified 106 patients who received SBRT between 2015 and 2018 for a primary or metastatic lung tumor with at least 12 months of follow up. Exclusion criteria were incomplete records, previous ipsilateral thoracic radiation, or relevant prior trauma. Computed tomography (CT) images were reviewed to identify and characterize rib fractures. Multivariate logistic regression modeling was employed to determine clinical, demographic, and procedural risk factors (e.g., age, sex, race, medical comorbidities, dosage, and tumor location).

Results

A total of 106 patients with 111 treated tumors met the inclusion criteria, 35 (32%) of whom developed at least one fractured rib (60 total fractured ribs). The highest number of fractured ribs per patient was five. Multivariate regression identified posterolateral tumor location as the only independent risk factor for rib fracture. On CT, fractures showed discontinuity between healing edges in 77% of affected patients.

Conclusions

Nearly one third of patients receiving SBRT for lung tumors experienced rib fractures, 34% of whom experienced pain. Many patients developed multiple fractures. Post-SBRT fractures demonstrated a unique discontinuity between the healing edges of the rib, a distinct feature of post-SBRT rib fractures. The only independent predictor of rib fracture was tumor location along the posterolateral chest wall. Given its increasing frequency of use, describing the risk profile of SBRT is vital to ensure patient safety and adequately inform patient expectations.
Literature
1.
go back to reference Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–6.CrossRefPubMedPubMedCentral Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–6.CrossRefPubMedPubMedCentral
2.
go back to reference Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a prospective phase II trial of medically inoperable stage I non–small-cell lung Cancer patients treated with stereotactic body Radiotherapy. J Clin Oncol. 2009;27(20):3290–6.CrossRefPubMed Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a prospective phase II trial of medically inoperable stage I non–small-cell lung Cancer patients treated with stereotactic body Radiotherapy. J Clin Oncol. 2009;27(20):3290–6.CrossRefPubMed
3.
go back to reference Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, et al. Stereotactic body Radiation Therapy for Operable Early-Stage Lung Cancer: findings from the NRG Oncology RTOG 0618 Trial. Jama Oncol. 2018;4(9):1263.CrossRefPubMedPubMedCentral Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, et al. Stereotactic body Radiation Therapy for Operable Early-Stage Lung Cancer: findings from the NRG Oncology RTOG 0618 Trial. Jama Oncol. 2018;4(9):1263.CrossRefPubMedPubMedCentral
4.
go back to reference Sharma A, Duijm M, de Hoop EO, Aerts JG, Verhoef C, Hoogeman M, et al. Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy. Acta Oncol. 2018;58(1):1–7. Sharma A, Duijm M, de Hoop EO, Aerts JG, Verhoef C, Hoogeman M, et al. Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy. Acta Oncol. 2018;58(1):1–7.
5.
go back to reference Lo H, Abel S, Finley G, Weksler B, Colonias A, Wegner RE. Surgical resection versus stereotactic body radiation therapy in early stage bronchopulmonary large cell neuroendocrine carcinoma. Thorac Cancer. 2019 Lo H, Abel S, Finley G, Weksler B, Colonias A, Wegner RE. Surgical resection versus stereotactic body radiation therapy in early stage bronchopulmonary large cell neuroendocrine carcinoma. Thorac Cancer. 2019
6.
go back to reference Rieber J, Streblow J, Uhlmann L, Flentje M, Duma M, Ernst I, et al. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases—A pooled analysis of the german working group “stereotactic radiotherapy. Lung Cancer. 2016;97:51–8.CrossRefPubMed Rieber J, Streblow J, Uhlmann L, Flentje M, Duma M, Ernst I, et al. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases—A pooled analysis of the german working group “stereotactic radiotherapy. Lung Cancer. 2016;97:51–8.CrossRefPubMed
7.
go back to reference Woody NM, Stephans KL, Marwaha G, Djemil T, Videtic GMM. Stereotactic body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy. Int J Radiat Oncol Biology Phys. 2015;92(2):325–31.CrossRef Woody NM, Stephans KL, Marwaha G, Djemil T, Videtic GMM. Stereotactic body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy. Int J Radiat Oncol Biology Phys. 2015;92(2):325–31.CrossRef
8.
go back to reference Stahl JM, Corso CD, Verma V, Park HS, Nath SK, Husain ZA, et al. Trends in stereotactic body radiation therapy for stage I small cell lung cancer. Lung Cancer. 2017;103:11–6.CrossRefPubMed Stahl JM, Corso CD, Verma V, Park HS, Nath SK, Husain ZA, et al. Trends in stereotactic body radiation therapy for stage I small cell lung cancer. Lung Cancer. 2017;103:11–6.CrossRefPubMed
9.
go back to reference Blom EF, Haaf K, ten, Arenberg DA, de Koning HJ. Uptake of minimally invasive surgery and stereotactic body radiation therapy for early stage non-small cell lung cancer in the USA: an ecological study of secular trends using the National Cancer Database. Bmj Open Respir Res. 2020;7(1):e000603.CrossRefPubMedPubMedCentral Blom EF, Haaf K, ten, Arenberg DA, de Koning HJ. Uptake of minimally invasive surgery and stereotactic body radiation therapy for early stage non-small cell lung cancer in the USA: an ecological study of secular trends using the National Cancer Database. Bmj Open Respir Res. 2020;7(1):e000603.CrossRefPubMedPubMedCentral
10.
go back to reference Taremi M, Hope A, Lindsay P, Dahele M, Fung S, Purdie TG, et al. Predictors of radiotherapy induced bone injury (RIBI) after stereotactic lung radiotherapy. Radiat Oncol Lond Engl. 2012;7(1):159.CrossRef Taremi M, Hope A, Lindsay P, Dahele M, Fung S, Purdie TG, et al. Predictors of radiotherapy induced bone injury (RIBI) after stereotactic lung radiotherapy. Radiat Oncol Lond Engl. 2012;7(1):159.CrossRef
11.
go back to reference Okoukoni C, Lynch SK, McTyre ER, Randolph DM, Weaver AA, Blackstock AW, et al. A cortical thickness and radiation dose mapping approach identifies early thinning of ribs after stereotactic body radiation therapy. Radiother Oncol. 2016;119(3):449–53.CrossRefPubMed Okoukoni C, Lynch SK, McTyre ER, Randolph DM, Weaver AA, Blackstock AW, et al. A cortical thickness and radiation dose mapping approach identifies early thinning of ribs after stereotactic body radiation therapy. Radiother Oncol. 2016;119(3):449–53.CrossRefPubMed
12.
go back to reference Roy SF, Louie AV, Liberman M, Wong P, Bahig H. Pathologic response after modern radiotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2019;0(0):124–34.CrossRef Roy SF, Louie AV, Liberman M, Wong P, Bahig H. Pathologic response after modern radiotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2019;0(0):124–34.CrossRef
13.
go back to reference Chipko C, Ojwang J, Gharai LR, Deng X, Mukhopadhyay N, Weiss E. Characterization of chest Wall Toxicity during Long Term follow up after thoracic stereotactic body Radiotherapy. Pract Radiat Oncol. 2019;9(3):e338–46.CrossRefPubMedPubMedCentral Chipko C, Ojwang J, Gharai LR, Deng X, Mukhopadhyay N, Weiss E. Characterization of chest Wall Toxicity during Long Term follow up after thoracic stereotactic body Radiotherapy. Pract Radiat Oncol. 2019;9(3):e338–46.CrossRefPubMedPubMedCentral
14.
go back to reference Kim SS, Song SY, Kwak J, Ahn SD, Kim JH, Lee JS, et al. Clinical prognostic factors and grading system for rib fracture following stereotactic body radiation therapy (SBRT) in patients with peripheral lung tumors. Lung Cancer. 2013;79(2):161–6.CrossRefPubMed Kim SS, Song SY, Kwak J, Ahn SD, Kim JH, Lee JS, et al. Clinical prognostic factors and grading system for rib fracture following stereotactic body radiation therapy (SBRT) in patients with peripheral lung tumors. Lung Cancer. 2013;79(2):161–6.CrossRefPubMed
15.
go back to reference Ricardi U, Frezza G, Filippi AR, Badellino S, Levis M, Navarria P, et al. Stereotactic ablative radiotherapy for stage I histologically proven non-small cell lung cancer: an italian multicenter observational study. Lung Cancer. 2014;84(3):248–53.CrossRefPubMed Ricardi U, Frezza G, Filippi AR, Badellino S, Levis M, Navarria P, et al. Stereotactic ablative radiotherapy for stage I histologically proven non-small cell lung cancer: an italian multicenter observational study. Lung Cancer. 2014;84(3):248–53.CrossRefPubMed
16.
go back to reference Lagerwaard FJ, Haasbeek CJA, Smit EF, Slotman BJ, Senan S. Outcomes of risk-adapted fractionated stereotactic Radiotherapy for Stage I non–small-cell Lung Cancer. Int J Radiat Oncol Biology Phys. 2008;70(3):685–92.CrossRef Lagerwaard FJ, Haasbeek CJA, Smit EF, Slotman BJ, Senan S. Outcomes of risk-adapted fractionated stereotactic Radiotherapy for Stage I non–small-cell Lung Cancer. Int J Radiat Oncol Biology Phys. 2008;70(3):685–92.CrossRef
17.
go back to reference Asai K, Shioyama Y, Nakamura K, Sasaki T, Ohga S, Nonoshita T, et al. Radiation-Induced Rib Fractures after Hypofractionated Stereotactic Body Radiation Therapy: risk factors and dose–volume relationship. Int J Radiat Oncol Biology Phys. 2012;84(3):768–73.CrossRef Asai K, Shioyama Y, Nakamura K, Sasaki T, Ohga S, Nonoshita T, et al. Radiation-Induced Rib Fractures after Hypofractionated Stereotactic Body Radiation Therapy: risk factors and dose–volume relationship. Int J Radiat Oncol Biology Phys. 2012;84(3):768–73.CrossRef
18.
go back to reference Oldenborg S, Valk C, van Os R, Oei B, Venselaar J, Vörding PZVS, et al. Rib fractures after reirradiation plus hyperthermia for recurrent breast cancer. Strahlenther Onkol. 2016;192(4):240–7.CrossRefPubMedPubMedCentral Oldenborg S, Valk C, van Os R, Oei B, Venselaar J, Vörding PZVS, et al. Rib fractures after reirradiation plus hyperthermia for recurrent breast cancer. Strahlenther Onkol. 2016;192(4):240–7.CrossRefPubMedPubMedCentral
20.
go back to reference Liebsch C, Seiffert T, Vlcek M, Beer M, Huber-Lang M, Wilke HJ. Patterns of serial rib fractures after blunt chest trauma: an analysis of 380 cases. PLoS ONE. 2019;14(12):e0224105.CrossRefPubMedPubMedCentral Liebsch C, Seiffert T, Vlcek M, Beer M, Huber-Lang M, Wilke HJ. Patterns of serial rib fractures after blunt chest trauma: an analysis of 380 cases. PLoS ONE. 2019;14(12):e0224105.CrossRefPubMedPubMedCentral
21.
go back to reference Pettersson N, Nyman J, Johansson KA. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose– and volume–response analysis. Radiother Oncol. 2009;91(3):360–8.CrossRefPubMed Pettersson N, Nyman J, Johansson KA. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose– and volume–response analysis. Radiother Oncol. 2009;91(3):360–8.CrossRefPubMed
Metadata
Title
Predictors and characteristics of Rib fracture following SBRT for lung tumors
Authors
Michael P. Carducci
Baskaran Sundaram
Benjamin A. Greenberger
Maria Werner-Wasik
Gregory C. Kane
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Rib Fracture
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10776-8

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine